OncoMatch/Clinical Trials/NCT03818334
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Is NCT03818334 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Cyclophosphamide and ATG for bone marrow transplant complications.
Treatment: Cyclophosphamide · ATG — This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Performance status
HCT-CI 0–3
Demographics
Prior therapy
Cannot have received: allogeneic bone marrow transplantation
Lab requirements
Kidney function
glomerular filtration rate < 50 mL.hour excluded
Cardiac function
heart ejection fraction < 45% excluded
Severe organic disfunction (heart ejection fraction < 45%, glomerular filtration rate < 50 mL.hour, pulmonary DLCO < 50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03818334 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic bone marrow transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify